Ucb Biopharma Srl
Clinical trials sponsored by Ucb Biopharma Srl, explained in plain language.
-
New lupus drug shows promise in major trial
Disease control Recruiting nowThis study tests if adding dapirolizumab pegol to standard lupus treatments can better control moderate to severe disease. About 450 adults with active lupus will receive the drug or a placebo for 48 weeks. The goal is to reduce lupus symptoms and flares without worsening overall…
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated May 21, 2026 05:11 UTC
-
New hope for painful hand and foot blisters: drug trial underway
Disease control Recruiting nowThis study tests an investigational drug called bimekizumab against a placebo in 300 adults with palmoplantar pustulosis (PPP), a skin condition causing painful pus-filled blisters on the palms and soles. The goal is to see if the drug can clear or nearly clear the skin lesions b…
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated May 21, 2026 05:11 UTC
-
Could an IV drip replace the needle for arthritis patients?
Disease control Recruiting nowThis study compares two ways of giving bimekizumab—an IV infusion versus a standard shot—to see if the IV works just as well. About 392 adults with active psoriatic arthritis or axial spondyloarthritis will take part. The main goal is to check drug levels in the blood and watch f…
Phase: PHASE1 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated May 20, 2026 11:57 UTC
-
Promising drug trial for teens with severe skin disease
Disease control Recruiting nowThis study tests a drug called bimekizumab in children and teenagers aged 9 to 17 with moderate to severe hidradenitis suppurativa, a painful skin condition that causes boils. The main goal is to see how the drug moves through the body and if it is safe. About 40 participants wil…
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
Promising drug for kids with rare muscle disease moves to next phase
Disease control Recruiting nowThis study tests an investigational drug called zilucoplan in 8 children (ages 2-17) with generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to see how the drug moves through the body, its safety, and whether it helps control symptoms. Participant…
Phase: PHASE2, PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated May 19, 2026 11:48 UTC
-
New hope for teens with severe psoriasis: drug showdown begins
Disease control Recruiting nowThis study compares two injectable drugs, bimekizumab and ustekinumab, in children and teens aged 6 to 17 with moderate to severe plaque psoriasis. The goal is to see which one works better at clearing skin and reducing redness, thickness, and scaling. Participants will be random…
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated May 19, 2026 11:47 UTC
-
New hope for kids with rare Muscle-Weakening disease
Disease control Recruiting nowThis study tests a drug called rozanolixizumab in 12 children aged 2 to 17 with moderate to severe generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to see if the drug is safe and helps control symptoms. Participants receive the drug as a shot un…
Phase: PHASE2, PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated May 18, 2026 12:12 UTC
-
New epilepsy drug tested for Long-Term safety in kids
Disease control Recruiting nowThis study looks at the long-term safety of the drug brivaracetam in children and teenagers with absence epilepsy (brief staring spells). About 120 participants who have already taken the drug in earlier studies will continue taking it and be monitored for side effects. The goal …
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated May 18, 2026 12:09 UTC
-
New inhaler aims to halt seizures in 90 seconds
Disease control Recruiting nowThis study tests an inhaled medication called Staccato alprazolam to see if it can stop a prolonged seizure within 90 seconds and prevent it from coming back for at least 2 hours. It is for people aged 12 and older who have predictable, long-lasting seizures. The trial compares t…
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New hope for kids with arthritis? drug trial launches for young patients
Disease control Recruiting nowThis study tests a drug called bimekizumab in children aged 2 to 17 with active juvenile arthritis (enthesitis-related arthritis or juvenile psoriatic arthritis). The goal is to measure how the drug moves through the body and check for side effects. About 40 children will take pa…
Phase: PHASE3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New study checks drug levels in breast milk of nursing moms
Knowledge-focused Recruiting nowThis study looks at how much of the drug bimekizumab passes into the breast milk of mothers who are already taking it for conditions like psoriasis or arthritis. About 20 breastfeeding women will provide milk samples over several weeks. The goal is to understand possible exposure…
Phase: PHASE1 • Sponsor: UCB Biopharma SRL • Aim: Knowledge-focused
Last updated May 20, 2026 11:53 UTC
-
New study checks if drug zilucoplan seeps into breast milk
Knowledge-focused Recruiting nowThis study looks at how much of the drug zilucoplan and its breakdown products end up in the breast milk of healthy women who are breastfeeding. About 15 women who are at least 6 weeks postpartum and plan to stop breastfeeding will take daily injections of zilucoplan. Researchers…
Phase: PHASE1 • Sponsor: UCB Biopharma SRL • Aim: Knowledge-focused
Last updated May 18, 2026 12:11 UTC
-
Healthy volunteers needed to test new Drug's safety
Knowledge-focused Recruiting nowThis early-stage study is testing a new drug called UCB5285 in healthy adults, including people of Japanese descent. The main goal is to see if the drug is safe and how the body processes it. About 96 participants will receive either the drug or a placebo. This study does not aim…
Phase: PHASE1 • Sponsor: UCB Biopharma SRL • Aim: Knowledge-focused
Last updated May 18, 2026 11:58 UTC